A 60-year-old female who underwent TACE twice for HCC visited our clinic after a bladder mass was found in a follow-up computed tomography (CT) scan. A 60-year-old female was found to be positive for hepatitis B surface antigen in a laboratory test. However, the patient denied both a history of hepatitis B and a family history. Therefore, HBV DNA test and abdominal ultrasonography were performed to work up the first diagnosis of hepatitis B. The HBV DNA test was confirmed to be positive. Liver cirrhosis and 3.6 cm sized HCC in segment 5 with infiltrative HCC in segment 8 were founded on abdominal ultrasound and liver dynamic CT. For accurate diagnosis of the hepatic mass lesion suspected of HCC, we carried out enhanced liver dynamic magnetic resonance imaging (MRI) and liver biopsy on the S5 mass. As a result, HCC was diagnosed without evidence of portal vein invasion, lymph node metastasis, or distant metastasis. For multiple intrahepatic masses, we performed TACE immediately after diagnosis and at 5 mo after the 1st TACE on the main mass. TACE was performed by infusion of Adriamycin (50 mg) and lipiodol (10 mL) mixture, followed by embolization with gelfoam. After the second TACE, a urinary bladder tumor was newly discovered on liver dynamic CT performed to confirm treatment response. The patient had a history of hysterectomy for uterine myoma 20 years ago. She was taking amlodipine 10 mg and olmesartan 40 mg as antihypertensive drugs. No special notes. At the time of admission, the patient was 152.0 cm tall with a weight of 61.8 kg. Regarding her blood pressure, her systolic blood pressure was 124 mmHg and her diastolic blood pressure was 83 mmHg. Her heart rate (65 bpm) and body temperature (36.4°C) were normal. Her respiratory rate was also normal at 20 breaths per minute. Her mental status was alert. At the time of admission, the patient did not complain of any symptoms including abdominal pain. Abnormal findings such as ascites were not observed on abdominal examination. In the liver function test performed during hospitalization, her aspartate aminotransferase and alanine aminotransferase levels were 24 U/L and 15 U/L, respectively, and her total bilirubin level was 0.78 mg/dL, all of which were normal. Her prothrombin time international normalized ratio was 1.05, which was within the normal range. Her albumin level was at 4.0 g/dL, which was also within the normal range. Her HBV DNA test was negative (< 10 IU/mL) from 46.0 IU/mL after entecavir administration. No other coinfections including HCV were identified. Levels of alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) as tumor markers were found to be 3.9 ng/mL and 24.0 mAU/mL, respectively. She underwent TACE for HCC at S5 and S8 previously confirmed on CT. After the second TACE, a follow-up CT was taken one month later. On CT, a polypoid mass of 1 cm in the bladder which had not been seen in the previous study was observed without any viable HCC. Follow-up CT was taken three months later. After 3 mo, the bladder mass previously seen showed an increase in size from 1 cm to 1.8 cm. We additionally performed liver MRI, chest CT, and Positron emission tomography (PET)-CT. In these studies, probable viable HCCs at S8 were found. There were no other prominent distant metastases.